Prostate Cancer Combo Therapy Starting a Phase 3 Global Trial

Prostate Cancer Combo Therapy Starting a Phase 3 Global Trial
A new Phase 3 clinical study, the EORTC trial 1333, will compare the combination treatment of enzalutamide and RA-223, versus enzalutamide alone, in the overall survival of patients with castration-resistant prostate cancer metastatic to the bone. Androgen deprivation therapy, which includes several types of hormonal therapy, is usually used to reduce the levels of male hormones

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *